BLCO

ANALYST NOTE: BLCO (Bausch + Lomb Corporation) Date: 2026-06-13 Current Price: $14.87

1. Structural Readiness

State: Context-Only Conservative Entry: — Breakout Level: — Extension: — ATR Current: 2.7% (Productive)

Analysis:

2. Thesis Layer

Thesis Classification: TACTICAL / SETUP-LED Secular Thesis: None named at this date.

Analysis: There is no named macro or secular thesis attached to BLCO in the current context. This is a tactical, setup-led name. The conviction for this position must be derived entirely from the quality of the technical setup (which is currently undefined) and the underlying business fundamentals. No external macro drivers (e.g., specific regulatory shifts, demographic surges) are being applied as a primary thesis engine at this moment. The analysis relies strictly on the company's operational execution and the structural readiness of the chart, which is currently absent.

3. The Business

Company Overview: Bausch + Lomb Corporation is a leading global eye health company operating across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The company markets approximately 400 products in roughly 100 countries, ranging from contact lenses and surgical systems to nutritional supplements and prescription medications.

Business Model & Segments:

• Vision Care/Consumer Health: This segment accounts for 65% of Vision Care revenue (as of FY2025) and includes consumer eye care (Blink drops, PreserVision supplements) and contact lenses.
• Surgical: Comprises equipment (24%), implantables (24%), and consumables (52%) as of FY2025. This segment targets cataract, vitreous, and retinal interventions.
• Ophthalmic Pharmaceuticals: Develops and markets proprietary and generic prescription medications.

Operational Evidence (as of 2026-06-13):

• Revenue Guidance: In the Q1 2026 earnings transcript (2026-04-29), management raised full-year revenue guidance by $45 million to a range of $5.42 billion to $5.52 billion.
• Profitability Guidance: Management simultaneously raised full-year adjusted EBITDA guidance by $10 million to a range of $1.01 billion to $1.06 billion.
• Product Performance:
• Miebo: Generated $76 million in Q1 2026 revenue, up 33% year-over-year.
• Xiidra: Generated $87 million in Q1 2026 revenue, up 30% year-over-year.
• Mix Shift: Premium products represented 26% of Q1 sales, up from 19% the prior year. Global mix increased to 13% from 10%.
• Pipeline & Launches:
• LUMIFY NXT: The NDA was filed in Q1 2026 (formerly LUMIFY Luxe).
• seeLYRA: CE Mark submission completed; trial recruitment on track.
• PreserVision AREDS3: Now available nationwide on retail shelves and online.
• Blink Triple Care: Planned for launch in the U.S. during 2026.
• Capital Structure:
• On June 26, 2025, the company amended its credit facility to include a new $800 million revolving credit facility maturing in 2030 and a $2.325 billion term B loan facility maturing in 2031.
• Issued €675 million in Senior Secured Floating Rate Notes due January 2031.

4. Archetype and Conviction

Archetype: Quality Compounder / Growth Leader Valuation Context: The financial spine indicates a forward consensus EPS of $0.806 for FY1 and $1.074 for FY2. At a current price of $14.87, the stock trades at approximately 18.4x FY1 EPS and 13.8x FY2 EPS.

Conviction Stack:

• Thesis Strength: Low (No named macro thesis; purely tactical).
• Evidence Quality: High. The company has demonstrated consistent execution with double-digit growth in key franchises (Miebo, Xiidra) and successful guidance raises. The capital structure is robust with long-dated debt facilities.
• Structural Quality: Undefined. The setup state is "context-only." There is no structural quality to assess regarding entry, stop, or breakout potential at this specific moment.
• Setup Readiness: None. No coil is forming or confirmed.
• Rerating Potential: Moderate to High based on fundamentals (mix shift to premium, new product launches), but currently unactionable due to the lack of a defined technical setup.

ATR Context: The current ATR of 2.7% is "productive" and sits within the standard range for sizing. It is not in the "high" (4-6%) or "extreme" (>8%) buckets, suggesting manageable volatility for a name of this size, provided a setup were to form.

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Fundamental Acceleration: Continued double-digit growth in Miebo and Xiidra, or faster-than-expected adoption of LUMIFY NXT.
• Guidance Raises: Further upward revisions to full-year revenue or EBITDA guidance in subsequent quarters.

What Would Invalidate the Case:

• Fundamental Miss: Failure to meet the raised guidance of $5.42–$5.52 billion revenue or $1.01–$1.06 billion EBITDA.
• Pipeline Delays: Significant delays in the NDA filing or approval for LUMIFY NXT or seeLYRA.

Gaps in Evidence:

• Sector Classification: The specific industry classification is missing from the current data.
• Archetype Source: No specific archetype source is cited for the "Quality Compounder" classification, though it is inferred from the growth data.

PRIVATE ANALYST CALL

Judgment: Hold Confidence: medium Key evidence: Raised full-year revenue guidance to $5.42-$5.52B; Miebo and Xiidra showing 30%+ YoY growth; robust capital structure with new $3.1B+ debt facilities. Key risks: No defined technical setup or entry point; lack of named macro thesis; potential execution risk on new product launches (LUMIFY NXT, seeLYRA). Sizing hint: N/A (No setup defined; position sizing is contingent on future structural formation). Expected path: Management expects continued premium mix shift and revenue growth through 2026; structural setup must form before capital deployment. Expected horizon: Indefinite until technical setup forms.